title: Triglyceride metabolism in heterozygote of Watanabe heritable hyperlipidemic rabbit.
abstract: The present study was conducted in order to examine the role of low-density lipoprotein (LDL)-receptor activity in very-low-density lipoprotein (VLDL) triglyceride metabolism in vivo. Fructose-feeding (10% in drinking water) for 2 weeks resulted in elevated plasma triglyceride in heterozygote of Watanabe heritable hyperlipidemic (WHHL) rabbit (WHHLH) associated with suppressed fractional catabolic rate (FCR) of plasma triglyceride, whereas Japanese white (JW) rabbit with normal LDL receptor activity showed no remarkable change in plasma triglyceride turnover after fructose-feeding, suggesting an involvement of LDL receptor activity on triglyceride metabolism. Thereafter, in order to stimulate cellular LDL receptor activity, fluvastatin, a new 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitor, was administered orally (1.52 +/- 0.26 mg/kg) to fructose-fed WHHLH. Significant suppression of triglyceride secretion rate (TGSR) was observed after treatment. However, since plasma triglyceride level was markedly suppressed, FCR of plasma triglyceride was significantly elevated by fluvastatin. Thus, it is speculated from the present data that LDL receptor activity is significantly involved in VLDL triglyceride metabolism in rabbits.
authors.affiliation: Second Department of Internal Medicine, Kobe University School of Medicine, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Naka
authors.forename: G
authors.initials: G
authors.lastname: Yoshino
authors.forename: T
authors.initials: T
authors.lastname: Hirano
authors.forename: Y
authors.initials: Y
authors.lastname: Murata
authors.forename: E
authors.initials: E
authors.lastname: Maeda
authors.forename: T
authors.initials: T
authors.lastname: Kazumi
authors.forename: M
authors.initials: M
authors.lastname: Kasuga
mesh_terms: D000818:Animals; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology; D000077340:Fluvastatin; D005632:Fructose / Q000008:administration & dosage; D006579:Heterozygote; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D006949:Hyperlipidemias / Q000235:genetics / Q000378:metabolism*; D007211:Indoles / Q000494:pharmacology; D008049:Lipase / Q000097:blood; D008071:Lipoprotein Lipase / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood / Q000378:metabolism*; D011817:Rabbits; D011973:Receptors, LDL / Q000187:drug effects / Q000378:metabolism; D014280:Triglycerides / Q000097:blood / Q000378:metabolism*
chemical_list: D005229:Fatty Acids, Monounsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D008079:Lipoproteins, VLDL; D011973:Receptors, LDL; D014280:Triglycerides; C030106:very low density lipoprotein triglyceride; D005632:Fructose; D000077340:Fluvastatin; D008049:Lipase; D008071:Lipoprotein Lipase